Lower-dose emicizumab prophylaxis: can less be more?

J Thromb Haemost. 2024 Apr;22(4):922-925. doi: 10.1016/j.jtha.2024.01.018.

Authors

Alok Srivastava¹, Alfonso Iorio²

Affiliations

¹ Department of Haematology, Christian Medical College Vellore, Ranipet Campus, Tamil Nadu, India. Electronic address: [email protected].
² Department of Health Research Methods, Evidence, and Impact, and Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

PMID: 38521578
DOI: 10.1016/j.jtha.2024.01.018

No abstract available

MeSH terms

Antibodies, Bispecific* / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Factor VIII
Hemophilia A* / diagnosis
Hemophilia A* / drug therapy
Hemorrhage / chemically induced
Hemorrhage / prevention & control
Humans

Substances

emicizumab
Factor VIII
Antibodies, Bispecific
Antibodies, Monoclonal, Humanized